// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

BIOSAMPLES FROM AT RISK SSC PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA: OPPORTUNITY FOR DIAGNOSIS OF PRE-CLINICAL SSC

R. Ross - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

BMI AND TREATMENT SURVIVAL IN RA PATIENTS STARTING TREATMENT WITH TNFΑ-INHIBITORS: LONG TERM FOLLOW-UP IN THE REAL LIFE METEOR REGISTRY

S. A. Bergstra - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

Glucocorticoid

BIOSIMILAR SWITCHING PROCESS - UK PATIENTS’ EXPERIENCE STUDY

C. Jacklin - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

R. Furie - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus nephritis

Belimumab

BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIGUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)

O. Distler - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Scleroderma

Riociguat

BUDGET IMPACT ANALYSIS OF INTRODUCING SUBCUTANEOUS INFLIXIMAB CT-P13 SC FROM THE UK PAYER PERSPECTIVE

M. Perry - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Infliximab

BURTON PATIENT REPORTED OUTCOME MEASURES (B-PROM): STEPS TOWARDS VALIDATION

R. Laxminarayan - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Preterm premature rupture of the membranes

N/A

CAN A SPECIALIST NURSE REPLACE A CONSULTANT - AN INNOVATIVE MODEL FOR OSTEOPOROSIS CARE

J. Begum - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

Hydroxyzine

CAN A GCA RISK STRATIFICATION SCORE BE HELPFUL IN CLINICAL PRACTICE?

M. Jasim - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

SJ8903

CAN DEDICATED COMMUNITY HEALTH HUBS IMPROVE PHYSICAL ACTIVITY IN A MULTI-ETHNIC RHEUMATOLOGY PRACTICE?

J. Begum - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CANNABINOIDS: FRIEND OR FOE OR A BYSTANDER?

N. Jain - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CARDIO- AND CEREBROVASCULAR RISK WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS) IN RHEUMATOID ARTHRITIS (RA): A REAL-WORLD COMPARATIVE ASSESSMENT

A. Prats-Uribe - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

CARDIAC MRI IN HYPERFERRITINAEMIC DISEASE STATES REVEALS MYOCARDIAL INFLAMMATION NOT IDENTIFIED BY ECHOCARDIOGRAPHY

S. El-Ghazali - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CARTILAGE REPAIR ACTIVITY DURING JOINT-PRESERVING TREATMENT MAY BE ACCOMPANIED BY OSTEOPHYTE FORMATION

M. Jansen - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CASE-BASED ONLINE EDUCATION SIGNIFICANTLY INCREASES CLINICIAN COMPETENCE IN ASSESSING SSC-ILD DISEASE PROGRESSION AND IMPLEMENTING APPROPRIATE THERAPY

C. Rohani-Montez - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CHANGE IN DISEASE ACTIVITY AND TREATMENT RESPONSE AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE FROM THE UK

S. Henning - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Abatacept

CHANGES IN ILLNESS PERCEPTIONS IN PEOPLE WITH RHEUMATOID ARTHRITIS OVER THE FIRST YEAR OF TREATMENT WITH METHOTREXATE

J. Gwinnutt - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Rheumatoid arthritis

Methotrexate

CHANGES IN THE VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGFA) SPLICING AXIS IN HUMAN SYNOVIUM ARE RELATED TO INFLAMMATION IN ARTHRITIS

D. Amanitis - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

CHARACTERISTICS OF MYOSITIS SPECTRUM DISEASE - RHEUMATOID ARTHRITIS OVERLAP CASES IN A HUNGARIAN COHORT

L. Bodoki - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Rheumatoid arthritis

N/A

CHARACTERIZATION OF SERIOUS INFECTIONS WITH UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS

K. Winthrop - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Copyright © 2026. QuantiNova All rights reserved